Navigation Links
Pre-clinical data shows Angiocidin effective against leukemia
Date:12/8/2012

Angiocidin, a novel tumor-inhibiting protein, has been shown to reduce acute myeloid leukemia (AML) cells in vivo by almost two-thirds in pre-clinical experiments.

George P. Tuszynski, a professor of neuroscience in Temple University's School of Medicine who discovered Angiocidin, will present the findings during the American Society of Hematology's national meeting in Atlanta on Dec. 9.

AML causes certain white blood cells to stop maturing, resulting in their uncontrolled proliferation, which can lead to suppression of the immune system and often fatal secondary problems such as infections, including pneumonia, and an increased risk for bleeding.

In earlier in vitro studies using four AML cell lines and patient AML cells, Angiocidin demonstrated the ability to stimulate maturation in the affected white cells, causing them to behave and function like normal cells.

With 50 percent success in the in vitro patient studies, the researchers next focused on how Angiocidin would perform against cells from AML patients in vivo. Samples from a patient were injected into a special mouse model developed by Martin Carroll, associate professor of medicine at the University of Pennsylvania. Over a 14 week period, the leukemia cells engrafted to the bone marrow of the mice.

The mice were then given doses of Ara-C, Angiocidin or a combination of both. The chemotherapy agent Ara-C, or cytosine arabinoside, is standard-of-care for AML and kills cancer cells by inhibiting DNA synthesis.

Mice treated only with Angiocidin saw a 63 percent reduction in AML cells, while those treated with both experienced a 79 percent reduction in AML cells. Mice treated with Ara-C alone saw a reduction of only around 40 percent.

"One question we had is whether Angiocidin would be able to get into the bone marrow," said Tuszynski. "These results clearly show that Angiocidin is able to prevent the growth of AML cells in the bone marrow." However, Tuszynski cautioned that pre-clinical data is not always predictive of activity in humans.

While Ara-C and other drugs used to treat AML are highly toxic, Angiocidin has exhibited no evidence of toxicity, making it a potentially safer alternative treatment to standard-of-care, especially for elderly patients who can't tolerate chemotherapy.

Tuszynski said that additional pre-clinical tests are being performed to gather more data and to determine an optimal dose of Angiocidin for patients. "Once we have all of our pre-clinical data together, we will be able to begin preparing for a clinical trial in humans," he said.

The pre-clinical testing of Angiocidin has been funded through a grant from Philadelphia's University City Science Center.

A start-up company, Diffregen LLC, has licensed Angiocidin from Temple. They recently submitted a small business innovation research (SBIR) grant proposal to the National Institutes of Health to support product development activities for this novel treatment for AML and potentially other cancers.


'/>"/>
Contact: Preston M. Moretz
pmoretz@temple.edu
215-204-4380
Temple University
Source:Eurekalert

Related medicine news :

1. Wellesley study shows income inequality a key factor in high US teen births
2. Invasive heart test being dramatically overused, Stanford study shows
3. Novel compound demonstrates anti-leukemic effect in zebrafish, shows promise for human treatment
4. Lung Cancer Screening Might Pay Off, Analysis Shows
5. Nonsurgical Method to Measure Brain Pressure Shows Promise
6. BMC study shows diverting passengers to elevators could help reduce falls at Logan Airport
7. Study Shows New Option for Kids With Tough-to-Treat Leukemia
8. Politics May Get in the Way of Empathy, Research Shows
9. Live imaging shows response to cancer drugs can be boosted by altering tumor microenvironment
10. Experimental Pill for Multiple Sclerosis Shows Promise
11. Mechanical tissue resuscitation technology shows promise
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2016)... ... ... After a year and a half of planning the Multiple Pathways of Recovery Conference ... of Recovery Conference was held May 2 -4, 2016 at the Mystic Marriott Hotel ... to explore the many pathways individuals use to get into and sustain their recovery. ...
(Date:5/27/2016)... ... ... W.S. Badger Co. Inc ., the maker of certified organic and ... of the best small businesses for new dads by Fatherly, the digital lifestyle guide ... progressive benefits to new parents on the organization’s 2016 Best Places to Work ...
(Date:5/27/2016)... ... May 27, 2016 , ... In ... the many who are unaware of the plight of aphasia. In collaboration with ... the “Stroke Awareness” campaign. , The link between stroke and aphasia is relatively ...
(Date:5/27/2016)... ... May 27, 2016 , ... With a team of ... food industries. Aside from its GMP accreditation, Validation Center is also a registered ... products, services and staff. , Validation Center is ISO17025 accredited and only offers ...
(Date:5/26/2016)... St. Louis, Missouri (PRWEB) , ... May 26, ... ... optimal cost, quality and clinical outcomes, hosted members and suppliers for its inaugural ... with a focus on their mission of elevating the operational health of America’s ...
Breaking Medicine News(10 mins):
(Date:5/27/2016)... , May 27, 2016 ... biopharma company focused on the highly lucrative global ... substantial pipeline of potential first-in-class or best-in-class tyrosine ... in development with strategic partners. HCM,s profitable Chinese ... domestic market. We expect progress of the mid-to-late-stage ...
(Date:5/26/2016)... , May 26, 2016 According to ... Waste Management Market - U.S. Industry Analysis, Size, Share, Growth, ... market in the U.S. was valued at US$ 5.89 Bn ... of 3.4% from 2015 to 2023 to reach US$ 7.99 ... of current and emerging needle free drug delivery devices and ...
(Date:5/26/2016)... May 26, 2016 Since its ... into an essential life science tool for conducting genetic ... BCC Research reveals in its new report that the ... phase, one powered by a range of new applications ...      (Logo: http://photos.prnewswire.com/prnh/20140723/694805 ) , ...
Breaking Medicine Technology: